{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T13:43:26Z","timestamp":1792417406106,"version":"4.4.0"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Objectives:<\/jats:title>\n                    <jats:p>The role of early glucagon-like peptide-1 receptor agonist (GLP-1RA) therapy after acute ischemic stroke or high-risk transient ischemic attack remains uncertain. We performed a systematic review and meta-analysis of randomized evidence evaluating efficacy and safety in this setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidance, we included randomized controlled trials evaluating early GLP-1RA therapy in adults with acute ischemic stroke or high-risk transient ischemic attack. Risk ratios (RRs) with 95% confidence intervals (CIs) were pooled using inverse-variance random-effects models with restricted maximum likelihood estimation. The primary outcome was 90-day functional independence (modified Rankin Scale score: 0\u20132); mortality and symptomatic intracranial hemorrhage (sICH) were critical safety outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Four randomized trials enrolled 1,514 participants: LAMP, GALLOP-1, GALLOP-2, and TEXAIS. GLP-1RA therapy increased 90-day functional independence (547\/745 vs 516\/752; RR = 1.06; 95% CI: 1.01\u20131.11; I\n                      <jats:sup>2<\/jats:sup>\n                      = 5.8%), corresponding to an absolute risk difference of 4.8% and number needed to treat of 21. Mortality did not differ significantly (57\/749 vs 52\/756; RR = 1.13; 95% CI: 0.80\u20131.61; I\n                      <jats:sup>2<\/jats:sup>\n                      = 0%). sICH was not significantly different (23\/579 vs 20\/585; RR = 0.67; 95% CI: 0.13\u20133.42; I\n                      <jats:sup>2<\/jats:sup>\n                      = 67.0%). Excluding LAMP attenuated the functional effect (RR = 1.07; 95% CI: 0.92\u20131.24), and excluding GALLOP-2 yielded RR = 1.049 (95% CI: 0.999\u20131.102).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Early GLP-1RA therapy shows a possible functional benefit, but the finding is fragile and safety evidence remains imprecise. Larger dedicated stroke trials are required before routine clinical use.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/aian.aian_812_26","type":"journal-article","created":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T09:00:10Z","timestamp":1792054810000},"page":"685-696","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Early GLP-1 Receptor Agonist Therapy in Acute Ischemic Stroke and High-Risk Transient Ischemic Attack: A Systematic Review and Meta-analysis of Randomized Trials"],"prefix":"10.4103","volume":"29","author":[{"given":"Aasim","family":"Ali","sequence":"first","affiliation":[{"name":"Department of Neurology, Faisalabad Medical University, Faisalabad, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Csilla","family":"D\u00e9zsi","sequence":"additional","affiliation":[{"name":"Department of Neurology, Sz\u00e9cs\u00e9nyi University - University of Gy\u0151r, Gy\u0151r, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktor","family":"Guly\u00e1s-Oldal","sequence":"additional","affiliation":[{"name":"Department of Neurology, Dhankuta District Hospital, Dhankuta Province 1, Nepal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piresh","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Neurology, Dhankuta District Hospital, Dhankuta Province 1, Nepal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K\u00e1roly","family":"Szili","sequence":"additional","affiliation":[{"name":"Department of Neurology, Dhankuta District Hospital, Dhankuta Province 1, Nepal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sami","family":"Ullah","sequence":"additional","affiliation":[{"name":"Department of Neurology, Faisalabad Medical University, Faisalabad, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nimra","family":"Akram","sequence":"additional","affiliation":[{"name":"Department of Neurology, Faisalabad Medical University, Faisalabad, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Abdullah","family":"Gulzar","sequence":"additional","affiliation":[{"name":"Department of Neurology, Faisalabad Medical University, Faisalabad, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Azhar","sequence":"additional","affiliation":[{"name":"Department of Neurology, Faisalabad Medical University, Faisalabad, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Zain","family":"ul Abidin","sequence":"additional","affiliation":[{"name":"Department of Neurology, Faisalabad Medical University, Faisalabad, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Usama","family":"Saleem","sequence":"additional","affiliation":[{"name":"Department of Neurology, Faisalabad Medical University, Faisalabad, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Asad","family":"Shabbir","sequence":"additional","affiliation":[{"name":"Department of Neurology, Faisalabad Medical University, Faisalabad, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mukesh","family":"Sharma","sequence":"additional","affiliation":[{"name":"Department of Neurology, Dhankuta District Hospital, Dhankuta Province 1, Nepal"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,10,14]]},"reference":[{"key":"R1-20261019","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/S1474-4422(21)00252-0","article-title":"Global, regional, and national burden of stroke and its risk factors, 1990\u20132019: A systematic analysis for the Global Burden of Disease Study 2019","volume":"20","year":"2021","journal-title":"Lancet Neurol"},{"key":"R2-20261019","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1007\/s00125-024-06146-z","article-title":"Prevention and treatment of ischaemic and haemorrhagic stroke in people with diabetes mellitus: A focus on glucose control and comorbidities","volume":"67","author":"Sacco","year":"2024","journal-title":"Diabetologia"},{"key":"R3-20261019","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/s41569-023-00849-3","article-title":"Glucagon-like peptide 1 receptor agonists: Cardiovascular benefits and mechanisms of action","volume":"20","author":"Ussher","year":"2023","journal-title":"Nat Rev Cardiol"},{"key":"R4-20261019","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1177\/0271678X20952011","article-title":"Glucagon-like peptide-1 receptor agonists as neuroprotective agents for ischemic stroke: A systematic scoping review","volume":"41","author":"Maskery","year":"2021","journal-title":"J Cereb Blood Flow Metab"},{"key":"R5-20261019","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1177\/17474930241253988","article-title":"Glucagon-like peptide-1 receptor agonists and stroke: A systematic review and meta-analysis of cardiovascular outcome trials","volume":"19","author":"Adamou","year":"2024","journal-title":"Int J Stroke"},{"key":"R6-20261019","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1161\/STROKEAHA.125.053075","article-title":"GLP-1 receptor agonists as treatment of nondiabetic ischemic stroke: A systematic review and meta-analysis","volume":"57","author":"Michaelsen","year":"2026","journal-title":"Stroke"},{"key":"R7-20261019","doi-asserted-by":"crossref","first-page":"11795735261444425","DOI":"10.1177\/11795735261444425","article-title":"GLP-1 receptor agonists in acute ischemic stroke and secondary stroke prevention: A narrative review of preclinical and clinical evidence","volume":"18","author":"Samanidou","year":"2026","journal-title":"J Cent Nerv Syst Dis"},{"key":"R8-20261019","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1161\/STROKEAHA.123.044568","article-title":"Management of poststroke hyperglycemia: Results of the TEXAIS randomized clinical trial","volume":"54","author":"Bladin","year":"2023","journal-title":"Stroke"},{"key":"R9-20261019","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1001\/jamainternmed.2025.5684","article-title":"Liraglutide in acute minor ischemic stroke or high-risk transient ischemic attack with type 2 diabetes: The LAMP randomized clinical trial","volume":"186","author":"Zhu","year":"2026","journal-title":"JAMA Intern Med"},{"key":"R10-20261019","doi-asserted-by":"crossref","first-page":"11274","DOI":"10.1038\/s41467-025-66167-z","article-title":"Glucagon-like peptide-1 receptor agonist in large vessel occlusion treated by reperfusion therapy\u2014A phase 2 randomized trial","volume":"16","author":"Wang","year":"2025","journal-title":"Nat Commun"},{"key":"R11-20261019","article-title":"Glucagon like peptide 1receptor agonist in large vessel occlusion treated by endovascular therapy (GALLOP 2): A multicentre, prospective, randomised, open label, blinded endpoint trial","author":"Wang","year":"2026","journal-title":"SSRN"},{"key":"R12-20261019","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"R13-20261019","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: A revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"R14-20261019","year":"2024","journal-title":"Cochrane Handbook for Systematic Reviews of Interventions. Version 6.5"},{"key":"R15-20261019","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: An emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"R16-20261019","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1001\/jama.2019.9346","article-title":"Intensive vs standard treatment of hyperglycemia and functional outcome in patients with acute ischemic stroke: The SHINE randomized clinical trial","volume":"322","author":"Johnston","year":"2019","journal-title":"JAMA"},{"key":"R20-20261019","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"}],"container-title":["Annals of Indian Academy of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/aian.aian_812_26","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T13:03:05Z","timestamp":1792414985000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/aian.aian_812_26"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":17,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/aian.aian_812_26","relation":{},"ISSN":["0972-2327","1998-3549"],"issn-type":[{"value":"0972-2327","type":"print"},{"value":"1998-3549","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"2026-06-27","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-16","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}